Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK-1482160是一种CNS-渗透的P2X7受体负变构调节剂,具有口服活性。P2X7受体参与中枢和外周免疫细胞产生促炎细胞因子,因此GSK-1482160具有研究炎症性疾病的潜力。GSK-1482160具有出色的体外效价(在包括人类在内的多种物种的重组和初始P2X7受体的功能和电生理测试中)和交叉靶标选择性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
5 mg | ¥ 813 | 现货 | ||
10 mg | ¥ 1,310 | 现货 | ||
25 mg | ¥ 2,660 | 现货 | ||
50 mg | ¥ 3,980 | 现货 | ||
100 mg | ¥ 5,690 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 898 | 现货 |
产品描述 | GSK-1482160 is a CNS-penetrant negative allosteric modulator of P2X7 receptor with oral activity. The P2X7 receptor is involved in the production of pro-inflammatory cytokines by central and peripheral immune cells, so GSK-1482160 has the potential to study inflammatory diseases. GSK-1482160 shows excellent in vitro potency (in functional and electrophysiological assays at recombinant and naive P2X7 receptors across multiple species including humans) and cross-target selectivity. |
体外活性 | ATP-induced secretion of tau-containing exosome was significantly suppressed by GSK-1482160 treatment from primary murine microglia, but not from neurons or astrocytes [2]. |
体内活性 | Oral administration of GSK-1482160 significantly reduced accumulation of MC1+ and Alz50+ misfolded tau in hippocampal regions, which was accompanied with reduced accumulation of Tsg101, an exosome marker, in hippocampal neurons. GSK-1482160 also significantly increased accumulation of Tsg101 and CD81 in microglia in vivo, suggesting its suppression of P2RX7-induced exosome secretion from microglia [2]. |
分子量 | 334.72 |
分子式 | C14H14ClF3N2O2 |
CAS No. | 1001389-72-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (268.9 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9876 mL | 14.9379 mL | 29.8757 mL | 74.6893 mL |
5 mM | 0.5975 mL | 2.9876 mL | 5.9751 mL | 14.9379 mL | |
10 mM | 0.2988 mL | 1.4938 mL | 2.9876 mL | 7.4689 mL | |
20 mM | 0.1494 mL | 0.7469 mL | 1.4938 mL | 3.7345 mL | |
50 mM | 0.0598 mL | 0.2988 mL | 0.5975 mL | 1.4938 mL | |
100 mM | 0.0299 mL | 0.1494 mL | 0.2988 mL | 0.7469 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK-1482160 1001389-72-5 Membrane transporter/Ion channel Neuroscience P2X Receptor Inhibitor inhibitor inhibit